Quantum Biopharma Adds $1M to Crypto Treasury in Strategic Expansion
Quantum Biopharma has expanded its crypto treasury to $4.5 million with a new $1 million allocation to BTC and other digital assets. This strategy also aims to generate additional yield through staking.
Canadian biotech firm Quantum BioPharma Ltd. has announced an additional $1 million purchase of Bitcoin and other crypto assets, bringing its total digital investment to $4.5 million. The company plans to allocate part of the portfolio to staking, seeking to generate additional yield and hedge against volatility in the Canadian dollar.
Following the announcement, shares of QNTM surged by approximately 25%. Moreover, the company signaled its openness to accepting funding and conducting other transactions in crypto, depending on market conditions.
Quantum BioPharma Expands Its Crypto Treasury
The company has secured board approval for a $1 million investment in Bitcoin and other cryptocurrencies, bringing the company’s total crypto holdings to $4.5 million. According to the press release, all transactions are executed through a qualified custodian to ensure full compliance with financial and audit standards.
Related: Sei Expands into DeSci, Eyes Acquisition of Biotech Firm 23andMe
As part of its next phase, the company plans to allocate a portion of its digital assets to staking to earn consistent rewards from blockchain networks. Quantum also reserves the right to modify its crypto reserve strategy based on market dynamics and operational needs.
Market Reaction and Corporate Trends
Quantum BioPharma’s announcement received positive press and a favorable response from the stock market, positioning the company among a growing number of biopharmaceutical firms turning to crypto as part of their treasury strategies.
- Atai Life Sciences previously disclosed a $5 million Bitcoin purchase. In a post on X, Atai founder Christian Angermayer stated that Bitcoin “should be a part of ANY corporate treasury – especially, in fact, in the biotech sector.”
- In May, Singapore-based Basel Medical Group announced plans to invest $1 billion in BTC. However, its stock saw a sharp decline the following day.
According to BitcoinTreasuries.NET, corporate treasuries now hold over $83 billion in Bitcoin, making them the second-largest category of institutional holders after ETFs.
Company leaders emphasize that expanding crypto reserves helps diversify risk and unlock new revenue streams, particularly in sectors with long product development cycles.
Related: Tesla, MicroStrategy… and Now Nuvve! Another Company Joins the BTC Movement
The content on The Coinomist is for informational purposes only and should not be interpreted as financial advice. While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any content. Neither we accept liability for any errors or omissions in the information provided or for any financial losses incurred as a result of relying on this information. Actions based on this content are at your own risk. Always do your own research and consult a professional. See our Terms, Privacy Policy, and Disclaimers for more details.
Articles by this author
